OBP Company
Uniting Arabs
in a Borderless World
We have started from Oman for this unity of the Arab world. You
become the continuation of this chain.
Proudly introducing the leaders shaping our vision
Under the leadership of our Chairman and founder, Saad Moosa Al Junaibi , and an esteemed board: Dr. Ahmed Al Saidi , Esam Al Najjar , Zubair Corporation represented by Moosa Juma Al Hasani , and Montroi Sa , their expertise, commitment, and unwavering support are instrumental in making our vision a reality..
Chairman
Saad Al Junaibi
Member of the Board
Dr Ahmed Al Saidi
Member of the Board
Esam Al Najjar
Member of the Board
Zubair Corporation
Represented by Moosa Juma Al Hasani
Member of the Board
Montroi Sa
We pursue the miracles of science to protect people’s lives.
Improving Today,
Shaping Tomorrow's Health
Patient-Centric Approach
To improve patient outcomes by offering affordable and accessible treatments in biosimilar vaccines, oncology, immunotherapy, and gene therapy.
Address Unmet Medical Needs
To fill gaps in the healthcare landscape by researching and developing treatments for conditions with limited therapeutic options.
Collaboration for Innovation
Working together across industries and academic fields to push the boundaries in biopharmaceutical research.
OBP Landscape
Culture
At the intersection of our company culture and Oman’s rich traditions, we find a seamless fit. Both prioritize community, integrity, and a dedication to excellence—values that guide us as we strive to advance healthcare for all.
Leadership
Opal Bio Pharma was established in Oman with the aim of producing biosimilar vaccines replacing expensive biologic ones in order to reduce costs and produce vaccines and drugs with high shortages as soon as possible. In the continuation of this company’s mission, it is to first meet the country’s domestic needs and export to the GCC, then MENA, and finally middle-income countries in the world.
Strategy
OPAL BIOPHARMA (OBP), is an Oman-Based company with scientific and philanthropy purposes. Developing and producing biosimilar vaccines and medicines, finding the best ways for any treatment, and protecting every human life are all that we are planning to do.
With mass production, we are planning to export these vaccines from Oman to GCC countries, then MENA, and in the end, we want to provide middle-income countries all over the world. Besides developing vaccines and medicines, OBP is working with governments and NGOs to create awareness about prevention for people worldwide
Empowerment
Empowering individuals with tailored healthcare solutions that enhance well-being and offer a renewed sense of control over their health.
Sustainability
Committed to eco-conscious practices, our initiatives embrace sustainability, ensuring a healthier future for both patients and the planet.
Ethical Excellence
Upholding the highest ethical standards, we prioritize patient safety, transparency, and integrity in every aspect of our work.
Quality & Innovation
Our commitment to quality and innovation is validated by EMA and WHO approvals, underlining our adherence to the highest international standards. With all necessary licenses granted, we continue to push the boundaries in healthcare, merging regulatory compliance with groundbreaking research.
Corporate Responsibility
At Opal Bio Pharma, our commitment goes beyond medicine. We believe in the power of ethical choices to positively impact communities and improve lives. Through responsible business practices and a dedication to community welfare, we aim to create a lasting societal impact, today and for the future.
Empowering Lives Through Medical Innovation
We aim to lessen the impact of chronic diseases significantly.
Making preventions and treatments accessible in low-income countries is central to our commitment to global healthcare equality.
Enhancing the quality of life for all patients guides our development of therapies that go beyond treatment to improve well-being.
Reducing Toll, Expanding Access, Enhancing Life
We plan to have the production of expensive vaccines with shortages through biosimilar method and as soon as possible.
we plan to establish an R&D center to focus on chronic diseases and their treatments.
we plan to cooperate with NGOs to create awareness about the necessity of getting vaccinated.
Partners
